triazoles has been researched along with crizotinib in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, HM; Koudriakova, T; Romero, D; Skaptason, J; Tan, W; Vekich, S; Wilner, KD; Yamazaki, S | 1 |
| Zhang, HJ; Zhang, L; Zhang, XT | 1 |
| Acquaviva, J; Bates, RC; Camidge, DR; Doebele, RC; El-Hariry, I; Friedland, JC; He, S; Jiang, Q; Jimenez, JP; Lovly, CM; Morris, SW; Proia, DA; Sang, J; Sequeira, M; Shaw, AT; Smith, DL; Xue, L; Zhang, C | 1 |
| Beebe, K; Huang, Y; Miyajima, N; Mollapour, M; Neckers, L; Nonomura, K; Rivas, C; Shinohara, N; Sourbier, C; Tatokoro, M; Trepel, JB; Tsutsumi, S; Yoshida, S | 1 |
| Li, H; Sun, Y; Xu, F | 1 |
| Back, KR; Docherty, R; Doherty, CL; Feeder, N; Meenan, P; Pidcock, E; Reilly, AM; Sadiq, G | 1 |
| Ambrogio, C; Bombelli, S; Casati, C; Ceccon, M; Chiarle, R; Compagno, M; Di Giacomo, F; Gambacorti-Passerini, C; Giudici, G; Manazza, AD; Mastini, C; Menotti, M; Merlo, MEB; Mologni, L; Poggio, T; Rigolio, R; Turner, SD; Varesio, LM; Voena, C | 1 |
| Liu, H; Lu, S; Lu, T; Pan, J; Qiao, X; Xiang, B; Yan, L; Yuan, H; Zhang, L; Zhang, Y | 1 |
| Chen, KY; Fagin, JA; Ghossein, R; Knauf, JA; Luckett, KA; Socci, ND; Voza, F | 1 |
| Chen, L; Chen, W; Li, L | 1 |
1 review(s) available for triazoles and crizotinib
| Article | Year |
|---|---|
[Mechanisms of resistance to crizotinib in patients with transforming EML4-ALK fusion gene].
Topics: Apoptosis; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Triazoles | 2012 |
2 trial(s) available for triazoles and crizotinib
| Article | Year |
|---|---|
Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
Topics: Administration, Oral; Adult; Animals; Biological Availability; Cells, Cultured; Crizotinib; Dogs; Drug Evaluation, Preclinical; Half-Life; Hepatocytes; Humans; Macaca fascicularis; Male; Metabolic Clearance Rate; Microsomes, Liver; Middle Aged; Models, Molecular; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Rats; Rats, Sprague-Dawley; Triazoles; Young Adult | 2011 |
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
Topics: Adult; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mice, SCID; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays; Young Adult | 2013 |
7 other study(ies) available for triazoles and crizotinib
| Article | Year |
|---|---|
The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cells, Cultured; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; Female; HEK293 Cells; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Neoplasms; NIH 3T3 Cells; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Triazoles; Xenograft Model Antitumor Assays | 2013 |
Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.
Topics: Anaplastic Lymphoma Kinase; Animals; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Crizotinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Neuroblastoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured | 2014 |
The integration of solid-form informatics into solid-form selection.
Topics: Analgesics; Chemistry, Pharmaceutical; Crizotinib; Crystallization; Cyclohexanes; Databases, Factual; Drug Stability; Humans; Hydrogen Bonding; Informatics; Maraviroc; Molecular Conformation; Pharmaceutical Preparations; Pyrazoles; Pyridines; Technology, Pharmaceutical; Triazoles | 2015 |
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Cells, Cultured; Crizotinib; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Histones; Humans; Hydrazines; Lymphoma, Large-Cell, Anaplastic; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Microscopy, Confocal; Nucleophosmin; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; RNA Interference; Signal Transduction; Transplantation, Heterologous; Triazoles | 2016 |
Insight into the key features for ligand binding in Y1230 mutated c-Met kinase domain by molecular dynamics simulations.
Topics: Binding Sites; Crizotinib; Humans; Hydrogen Bonding; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Mutation; Protein Binding; Protein Domains; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Triazoles; Tyrosine | 2018 |
Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Cell Line, Tumor; Coumarins; Crizotinib; Disease Models, Animal; Drug Resistance, Neoplasm; Genes, p53; Humans; Indoles; MAP Kinase Signaling System; Mice; Mice, Transgenic; Mutation, Missense; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Pyrazines; Sulfonamides; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Triazoles | 2018 |
Use of Modeling and Simulation to Predict the Influence of Triazole Antifungal Agents on the Pharmacokinetics of Crizotinib.
Topics: Antifungal Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Fluconazole; Humans; Itraconazole; Lung Neoplasms; Triazoles; Voriconazole | 2022 |